Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis: The NORIG Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Gastroparesis remains a challenging syndrome to manage, with few effective treatments and a lack of rigorously controlled trials. Tricyclic antidepressants are often used to treat refractory symptoms of nausea, vomiting, and abdominal pain. Evidence from well-designed studies for this use is lacking. OBJECTIVE: To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis. DESIGN, SETTING, AND PARTICIPANTS: The NORIG (Nortriptyline for Idiopathic Gastroparesis) trial, a 15-week multicenter, parallel-group, placebo-controlled, double-masked, randomized clinical trial from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium (GpCRC), comparing nortriptyline with placebo for symptomatic relief in idiopathic gastroparesis. One hundred thirty patients with idiopathic gastroparesis were enrolled between March 2009 and June 2012 at 7 US academic medical centers. Patient follow-up was completed in October 2012. Inclusion criteria included delayed gastric emptying and moderate to severe symptom scores using the Gastroparesis Cardinal Symptom Index (GCSI). INTERVENTIONS Nortriptyline vs placebo. Study drug dose was increased at 3-week intervals (10, 25, 50, 75 mg) up to 75 mg at 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome measure of symptomatic improvement was a decrease from the patient's baseline GCSI score of at least 50% on 2 consecutive 3-week GCSI assessments during 15 weeks of treatment. RESULTS: The primary symptomatic improvement outcome did not differ between 65 patients randomized to nortriptyline vs 65 patients randomized to placebo: 15 (23% [95% CI, 14%-35%]) in the nortriptyline group vs 14 (21% [95% CI, 12%-34%]) in the placebo group (P = .86). Treatment was stopped more often in the nortriptyline group (19 [29% {95% CI, 19%-42%}]) than in the placebo group (6 [9%] {95% CI, 3%-19%}]) (P = .007), but numbers of adverse events were not different (27 [95% CI, 18-39] vs 28 [95% CI, 19-40]) (P = .89). CONCLUSIONS AND RELEVANCE: Among patients with idiopathic gastroparesis, the use of nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms. These findings do not support the use of nortriptyline for idiopathic gastroparesis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00765895.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Self-citationOn the Validity of the Beck Depression Inventory
Richter, P., Werner, J., Heerlein, A., Kraus, A., & Sauer, H. (1998) · Psychopathology · doi:10.1159/000066239 · Cited by 1,113
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Rentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406 · cited 1×
“0-30–min post satiety test 40 (13) 41 (15) 41 (14)”
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., & Veldhuyzen van Zanten, S. J. O. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.058 · Cited by 286
Mertz, H., Fass, R., Kodner, A., Yan-Go, F., Fullerton, S., & Mayer, E. A. (1998) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00160.x · Cited by 220
Similarities and differences between diabetic and idiopathic gastroparesis
Parkman, H. P., Yates, K., Hasler, W. L., Nguyen, L., Pasricha, P. J., Snape, W. J., Farrugia, G., Koch, K. L., Calles, J., Abell, T. L., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.013 · Cited by 205
Self-citation
Cited by
Camilleri, M., Chedid, V., Ford, A. C., Haruma, K., Horowitz, M., Jones, K. L., Low, P. A., Park, S.-Y., Parkman, H. P., & Stanghellini, V. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0038-z · Cited by 411
Self-citationThe stomach in health and disease
Hunt, R. H., Camilleri, M., Crowe, S. E., El-Omar, E. M., Fox, J. G., Kuipers, E. J., Malfertheiner, P., McColl, K. E. L., Pritchard, D. M., Rugge, M., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307595 · Cited by 403
Talley, N. J., Locke, G. R., Saito, Y. A., Almazar, A. E., Bouras, E. P., Howden, C. W., Lacy, B. E., DiBaise, J. K., Prather, C. M., Abraham, B. P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.020 · Cited by 333
Self-citationACG Clinical Guideline: Gastroparesis
Camilleri, M., Kuo, B., Nguyen, L., Vaughn, V. M., Petrey, J., Greer, K., Yadlapati, R., & Abell, T. L. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001874 · Cited by 332
“The central neuromodulator studied with the highest level of evidence was the tricyclic antidepressant, nortriptyline, in IG (104).”
BackgroundSelf-citationGastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
Metadata
- Authors
- Parkman, H. P., Van Natta, M. L., Abell, T. L., McCallum, R. W., Sarosiek, I., Nguyen, L., Snape, W. J., Koch, K. L., Hasler, W. L., Farrugia, G., Lee, L., Unalp-Arida, A., Tonascia, J., Hamilton, F., & Pasricha, P. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-12-25
- Volume
- 310
- Issue
- 24
- Pages
- 2640
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2047300129
- Cited by
- 176
- References
- 8
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis: The NORIG Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2013.282833
- The paper
- Parkman, H. P., Van Natta, M. L., Abell, T. L., McCallum, R. W., Sarosiek, I., Nguyen, L., Snape, W. J., Koch, K. L., Hasler, W. L., Farrugia, G., Lee, L., Unalp-Arida, A., Tonascia, J., Hamilton, F., & Pasricha, P. J. (2013). Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis: The NORIG Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2013.282833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.